Learn what deucravacitinib is, how selective TYK2 inhibition works, and key clinical trial results in moderate-to-severe plaque psoriasis. Discover its mechanism, benefits over traditional JAK inhibitors, and potential role as an oral alternative to biologics.
- admin@condrug.com
- Mon - Sat: 8.00 am - 7.00 pm
We develop solutions for your clinical data needs